黃仁勳:中國市場對美國公司十分重要 今次訪華之旅獲特朗普祝福
《央視新聞》報道,Nvidia(NVDA.US)行政總裁黃仁勳在北京表示,中國市場非常大兼且充滿活力,對美國公司十分重要。
他提到,AI在中國發展非常快,目前全球有50%的AI研究人員是位於中國,因此美國企業能夠紮根中國市場是非常重要。
黃仁勳於上周曾拜會美國總統特朗普,黃仁勳稱,特朗普知道他今次中國之旅,亦知道他將在旅途中發言,特朗普亦祝福他在中國旅途愉快。
今早(15日),Nvidia宣布計劃恢復向中國銷售H20晶片,因已獲美國政府通知H20晶片將可獲得出口許可。H20是Nvidia為符合美國出口規定而為中國市場開發的AI晶片,但自4月以來被美國政府禁止出口往中國。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.